阿司匹林预防子痫前期及相关疾病与死亡:美国预防服务工作组更新证据报告与系统评价
阿司匹林与子痫前期风险降低相关(RR 0.85, 95%CI 0.75–0.95),还降低围产期死亡(RR 0.79)、早产(RR 0.80)和宫内生长受限(RR 0.82),未增加产后出血等出血风险。结论支持对风险增加孕妇使用低剂量阿司匹林预防子痫前期,但多数试验以白人为主,外推需谨慎。
要点
- 阿司匹林还降低围产期死亡(RR 0.79, 95%CI 0.66–0.96)、早产(RR 0.80, 95%CI 0.67–0.95)和宫内生长受限(RR 0.82, 95%CI 0.68–0.99)。
- 阿司匹林未显著增加产后出血风险(RR 1.03, 95%CI 0.94–1.12)或其他出血相关危害。
- 子痫前期绝对风险降低在较大试验(n>300)中为1%–6%,围产期死亡绝对风险降低在3项最大试验中为0.5%–1.1%。
- 多数试验纳入以白人为主的人群,基于多种风险因素选择,外推到其他人群需谨慎。
适用人群与场景
- 基于临床风险因素或测量指标判定子痫前期风险高于一般人群的孕妇;18项RCT针对此人群。
- 多数试验纳入以白人为主的人群;原文未明确列出具体纳入/排除标准。
- 研究场景为孕期门诊预防,非急诊/ICU急性期处理。
诊断标准与关键阈值
- 原文未提及具体的子痫前期风险判定标准或评分界值;试验基于「临床风险因素或测量指标 associated with higher disease incidence than in the general population」选择风险增加人群。
- 子痫前期诊断标准原文未详述。
处置流程与药物剂量
- 对子痫前期风险增加的孕妇,孕期每日口服低剂量阿司匹林,剂量范围50 mg/d至150 mg/d(原文未指定具体起始孕周、频次调整或疗程)。
- 原文未提及给药途径(除口服外)、目标值或停药阈值。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的红旗征及对应处理。
研究设计与关键结果
- 子痫前期绝对风险降低在较大试验(n>300)中为1%–6%,较小试验中更大;围产期死亡绝对风险降低在3项最大试验中为0.5%–1.1%。
证据类型、等级与局限
- 证据类型:系统评价与meta分析,纳入良好和一般质量的RCT;为USPSTF更新证据报告。
- 局限:多数试验纳入以白人为主的人群;原文未提及其他局限(如开放标签、单中心等)。
对床旁实践的改变
- 支持对子痫前期风险增加的孕妇在孕期使用低剂量阿司匹林(50–150 mg/d)以降低子痫前期、围产期死亡、早产和宫内生长受限风险。
- 不改变急诊/ICU对子痫前期急性发作的处置;该证据针对孕期预防,非急性期治疗。
- 适用人群为基于临床风险因素或测量指标判定风险增加的孕妇;不适用于一般风险人群的常规预防(原文未提及一般人群预防)。
- 常见陷阱:将研究方案剂量范围(50–150 mg/d)误作固定推荐剂量;外推至非白人为主人群需谨慎。
指南或共识出处
- US Preventive Services Task Force(USPSTF)更新证据报告与系统评价;原文未提及具体指南名称、发布年份(在线发表信息未提供)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Preeclampsia is a hypertensive disorder of pregnancy that poses serious maternal and infant health risks. Previous systematic reviews have established benefits of low-dose aspirin taken during pregnancy to prevent preeclampsia and its sequelae.
OBJECTIVE: To update evidence for the US Preventive Services Task Force (USPSTF) on effectiveness of aspirin use in preventing preeclampsia in individuals at increased risk based on clinical risk factors or measurements associated with higher disease incidence than in the general population.
DATA SOURCES: Studies from previous USPSTF review (2014), literature published January 2013 through May 15, 2020, in MEDLINE, PubMed (for publisher-supplied records only), EMBASE, and Cochrane Central Register of Controlled Trials. Ongoing surveillance through January 22, 2021.
STUDY SELECTION: Good- and fair-quality randomized clinical trials (RCTs) of low-dose aspirin use during pregnancy to prevent preeclampsia among individuals at increased risk; studies conducted in general populations to evaluate potential harms.
DATA EXTRACTION AND SYNTHESIS: Dual article screening and risk-of-bias assessment. Study data abstracted into prespecified forms, checked for accuracy. Random-effects meta-analysis.
MAIN OUTCOMES AND MEASURES: Diagnosis of preeclampsia; adverse pregnancy health outcomes and complications including eclampsia, perinatal mortality, preterm birth, small for gestational age, and potential bleeding harms or infant/child harms from aspirin exposure.
RESULTS: A total of 23 randomized clinical trials (RCTs) (N = 26 952) were included; 18 were conducted among participants at increased preeclampsia risk. Aspirin dosages ranged from 50 mg/d to 150 mg/d. Most trials enrolled majority White populations selected based on a range of risk factors. The incidence of preeclampsia among the trials of participants at increased risk ranged from 4% to 30%. Aspirin use was significantly associated with lower risk of preeclampsia (pooled relative risk [RR], 0.85 [95% CI, 0.75-0.95]; 16 RCTs [n = 14 093]; I2 = 0%), perinatal mortality (pooled RR, 0.79 [95% CI, 0.66-0.96]; 11 RCTs [n = 13 860]; I2 = 0%), preterm birth (pooled RR, 0.80 [95% CI, 0.67-0.95]; 13 RCTs [n = 13 619]; I2 = 49%), and intrauterine growth restriction (pooled RR, 0.82 [95% CI, 0.68-0.99]; 16 RCTs [n = 14 385]; I2 = 41%). There were no significant associations of aspirin use with risk of postpartum hemorrhage (pooled RR, 1.03 [95% CI, 0.94-1.12]; 9 RCTs [n = 23 133]; I2 = 0%) and other bleeding-related harms, or with rare perinatal or longer-term harms. Absolute risk reductions for preeclampsia associated with aspirin use ranged from -1% to -6% across larger trials (n >300) and were greater in smaller trials. For perinatal mortality, absolute risk reductions ranged from 0.5% to 1.1% in the 3 largest trials.
CONCLUSIONS AND RELEVANCE: Daily low-dose aspirin during pregnancy was associated with lower risks of serious perinatal outcomes for individuals at increased risk for preeclampsia, without evident harms.
参考来源
- Henderson JT, Vesco KK, Senger CA, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021. PMID: 34581730. doi:10.1001/jama.2021.8551
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。